Assertio Therapeutics Inc (ASRT)

Currency in USD
0.7035
-0.0072(-1.01%)
Closed·
After Hours
0.7049+0.0014(+0.20%)
·
ASRT Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected tomorrow
Fair Value
Day's Range
0.70010.7197
52 wk Range
0.51371.4500
Key Statistics
Prev. Close
0.7107
Open
0.7001
Day's Range
0.7001-0.7197
52 wk Range
0.5137-1.45
Volume
117.76K
Average Volume (3m)
255.55K
1-Year Change
-51.32%
Book Value / Share
1.13
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ASRT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
2.7500
Upside
+290.90%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Assertio Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Assertio Therapeutics Inc Company Profile

Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Employees
58

Assertio Therapeutics Inc Earnings Call Summary for Q1/2025

  • Q1 2025: GAAP net loss of $13.5M, revenue down to $26M from $31.9M YoY, gross margin up to 70% from 65%
  • Stock dipped 2.53% in aftermarket trading to $0.5998; analysts expect return to profitability this year
  • 2025 guidance maintained: revenue $108-122M, adjusted EBITDA $10-19M; focus on specialty pharma assets
  • CEO optimistic about strategic transactions in 2025 to expand commercial portfolio
  • Challenges: competitive market, legal exposure, pricing pressure on ROLVADON, declining revenue
Last Updated: 12/05/2025, 22:08
Read Full Transcript

Compare ASRT to Peers and Sector

Metrics to compare
ASRT
Peers
Sector
Relationship
P/E Ratio
−2.2x6.6x−0.5x
PEG Ratio
−0.020.210.00
Price/Book
0.6x1.1x2.6x
Price / LTM Sales
0.6x3.5x3.2x
Upside (Analyst Target)
323.0%104.3%42.0%
Fair Value Upside
Unlock9.7%6.6%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 2.7500
(+290.90% Upside)

Earnings

Latest Release
May 13, 2025
EPS / Forecast
-0.14 / -0.05
Revenue / Forecast
26.49M / 27.52M
EPS Revisions
Last 90 days

ASRT Income Statement

People Also Watch

17.070
QBTS
-3.40%
128.87
ALAB
+8.83%
57.89
TEM
-0.69%
231.12
ADI
+0.16%
5.300
GRAB
-0.19%

FAQ

What Stock Exchange Does Assertio Therapeutics Trade On?

Assertio Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Assertio Therapeutics?

The stock symbol for Assertio Therapeutics is "ASRT."

What Is the Assertio Therapeutics Market Cap?

As of today, Assertio Therapeutics market cap is 68.00M.

What Is Assertio Therapeutics's Earnings Per Share (TTM)?

The Assertio Therapeutics EPS (TTM) is -0.32.

When Is the Next Assertio Therapeutics Earnings Date?

Assertio Therapeutics will release its next earnings report on 30 Jul 2025.

From a Technical Analysis Perspective, Is ASRT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Assertio Therapeutics Stock Split?

Assertio Therapeutics has split 1 times.

How Many Employees Does Assertio Therapeutics Have?

Assertio Therapeutics has 58 employees.

What is the current trading status of Assertio Therapeutics (ASRT)?

As of 30 Jul 2025, Assertio Therapeutics (ASRT) is trading at a price of 0.70, with a previous close of 0.71. The stock has fluctuated within a day range of 0.70 to 0.72, while its 52-week range spans from 0.51 to 1.45.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.